JP2005517036A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005517036A5 JP2005517036A5 JP2003567389A JP2003567389A JP2005517036A5 JP 2005517036 A5 JP2005517036 A5 JP 2005517036A5 JP 2003567389 A JP2003567389 A JP 2003567389A JP 2003567389 A JP2003567389 A JP 2003567389A JP 2005517036 A5 JP2005517036 A5 JP 2005517036A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- composition
- activity
- treatment
- dopamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 30
- 239000000203 mixture Substances 0.000 claims 24
- 230000002401 inhibitory effect Effects 0.000 claims 20
- 229960003638 dopamine Drugs 0.000 claims 15
- 230000000694 effects Effects 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 12
- 230000000966 norepinephrine reuptake Effects 0.000 claims 11
- 239000004031 partial agonist Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 230000000697 serotonin reuptake Effects 0.000 claims 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 6
- 229940076279 serotonin Drugs 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 238000002474 experimental method Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 238000001690 micro-dialysis Methods 0.000 claims 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 2
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 206010051290 Central nervous system lesion Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 208000012239 Developmental disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 201000009916 Postpartum depression Diseases 0.000 claims 2
- 208000005793 Restless legs syndrome Diseases 0.000 claims 2
- 208000006289 Rett Syndrome Diseases 0.000 claims 2
- 208000036353 Rett disease Diseases 0.000 claims 2
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 229960002748 norepinephrine Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 208000019899 phobic disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000001932 seasonal effect Effects 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000016686 tic disease Diseases 0.000 claims 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000021703 chronic tic disease Diseases 0.000 claims 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000001730 monoaminergic effect Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000002474 noradrenergic effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20020076344 EP1336406A1 (en) | 2002-02-14 | 2002-02-14 | Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity |
| PCT/EP2003/050015 WO2003068207A2 (en) | 2002-02-14 | 2003-02-11 | Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005517036A JP2005517036A (ja) | 2005-06-09 |
| JP2005517036A5 true JP2005517036A5 (https=) | 2005-12-22 |
Family
ID=27619173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003567389A Withdrawn JP2005517036A (ja) | 2002-02-14 | 2003-02-11 | セロトニンおよび／またはノルアドレナリン阻害活性を持つドーパミン−ｄ２受容体部分アゴニスト |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050038015A1 (https=) |
| EP (2) | EP1336406A1 (https=) |
| JP (1) | JP2005517036A (https=) |
| KR (1) | KR20040081779A (https=) |
| CN (1) | CN1592614A (https=) |
| AU (1) | AU2003208714A1 (https=) |
| BR (1) | BR0306147A (https=) |
| CA (1) | CA2462688A1 (https=) |
| HR (1) | HRP20040276A2 (https=) |
| IL (1) | IL160942A0 (https=) |
| MX (1) | MXPA04004745A (https=) |
| NO (1) | NO20043833L (https=) |
| PL (1) | PL370632A1 (https=) |
| RU (1) | RU2004112546A (https=) |
| WO (1) | WO2003068207A2 (https=) |
| ZA (1) | ZA200404740B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001014330A2 (en) | 1999-08-23 | 2001-03-01 | Solvay Pharmaceuticals B.V. | Phenylpiperazines as serotonin reuptake inhibitors |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| AR032711A1 (es) | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene |
| AR032712A1 (es) | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen |
| ES2323451T7 (es) | 2001-07-20 | 2011-08-01 | Psychogenics Inc. | Tratamiento para el trastorno de hiperactividad con deficit de atencion. |
| KR100842694B1 (ko) | 2002-12-27 | 2008-07-01 | 오쓰까 세이야꾸 가부시키가이샤 | 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제 |
| AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
| GB0327195D0 (en) * | 2003-11-21 | 2003-12-24 | Smithkline Beecham Corp | Novel use |
| EP1595542A1 (en) * | 2004-03-26 | 2005-11-16 | Solvay Pharmaceuticals B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
| US7596407B2 (en) | 2004-03-26 | 2009-09-29 | Solvay Pharmaceuticals, B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
| WO2007019880A1 (en) * | 2005-08-18 | 2007-02-22 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of a selective inhibitor of norepinephrine reuptake for treating respiratory disorders resulting from rett syndrome |
| WO2007065713A2 (en) * | 2005-12-08 | 2007-06-14 | Axxonis Pharma Gmbh | Use of 8-alpha-ergolines for the treatment of traumatic brain disorders |
| JP2010518023A (ja) * | 2007-02-01 | 2010-05-27 | アラン アイ． グリーン | ドーパミンＤ２受容体遮断剤とノルエピネフリン再取り込み阻害剤およびノルエピネフリンα２受容体遮断剤との組み合わせ |
| SG183069A1 (en) * | 2007-07-23 | 2012-08-30 | Synosia Therapeutics | Treatment of post-traumatic stress disorder |
| TW200936130A (en) * | 2008-02-26 | 2009-09-01 | Lundbeck & Co As H | Uses of indane compounds |
| WO2011082266A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted heterocyclic compounds |
| CA2796722C (en) * | 2010-04-19 | 2021-06-01 | Nlife Therapeutics, S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| CN111134894B (zh) * | 2020-01-17 | 2022-02-22 | 上海长海医院 | 一种在体测定犬前列腺组织连续动态游离药物浓度的采样方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA71590C2 (en) * | 1998-11-13 | 2004-12-15 | Duphar Int Res | Piperazine and piperidine derivatives |
| WO2001014330A2 (en) * | 1999-08-23 | 2001-03-01 | Solvay Pharmaceuticals B.V. | Phenylpiperazines as serotonin reuptake inhibitors |
-
2002
- 2002-02-14 EP EP20020076344 patent/EP1336406A1/en not_active Withdrawn
-
2003
- 2003-02-11 CA CA002462688A patent/CA2462688A1/en not_active Abandoned
- 2003-02-11 PL PL03370632A patent/PL370632A1/xx not_active Application Discontinuation
- 2003-02-11 BR BR0306147-7A patent/BR0306147A/pt not_active IP Right Cessation
- 2003-02-11 CN CNA038015544A patent/CN1592614A/zh active Pending
- 2003-02-11 RU RU2004112546/15A patent/RU2004112546A/ru not_active Application Discontinuation
- 2003-02-11 WO PCT/EP2003/050015 patent/WO2003068207A2/en not_active Ceased
- 2003-02-11 MX MXPA04004745A patent/MXPA04004745A/es unknown
- 2003-02-11 AU AU2003208714A patent/AU2003208714A1/en not_active Abandoned
- 2003-02-11 US US10/490,365 patent/US20050038015A1/en not_active Abandoned
- 2003-02-11 JP JP2003567389A patent/JP2005517036A/ja not_active Withdrawn
- 2003-02-11 IL IL16094203A patent/IL160942A0/xx unknown
- 2003-02-11 EP EP03706621A patent/EP1476148A2/en not_active Withdrawn
- 2003-02-11 HR HR20040276A patent/HRP20040276A2/hr not_active Application Discontinuation
- 2003-02-11 KR KR10-2004-7012355A patent/KR20040081779A/ko not_active Ceased
-
2004
- 2004-06-15 ZA ZA200404740A patent/ZA200404740B/en unknown
- 2004-09-13 NO NO20043833A patent/NO20043833L/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005517036A5 (https=) | ||
| RU2004112546A (ru) | Частичная агонистическая активность в отношении d2 рецепторов допамина и/или ингибирующая активность в отношении норадреналина | |
| JP2022515766A5 (https=) | ||
| JP2022515158A5 (https=) | ||
| DE602006012459D1 (de) | Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a-beta-oligomere und verfahren zur herstellung dieser antikörper | |
| RU2012149042A (ru) | Конъюгат (варианты), способ лечения заболеваний нервной системы (варианты), способ визуализации клетки, диагностическое средство, амидные соединения (варианты), способ получения конъюгата и способы получения амидных соединений | |
| RU2018130727A (ru) | Органические соединения | |
| CY1112253T1 (el) | Ενωσεις διαμινοτριαζολιου χρησιμες ως αναστολεις κινασης πρωτεϊνης | |
| ATE457989T1 (de) | Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit | |
| JP2010524958A5 (https=) | ||
| ATE455463T1 (de) | Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren | |
| DE602004017174D1 (de) | Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege | |
| JP2006143749A5 (https=) | ||
| NO20076502L (no) | Pyrrolopyridiner nyttige som inhibitorer av proteinkinase | |
| JP2008501758A5 (https=) | ||
| JP2005523335A5 (https=) | ||
| JP2008503523A5 (https=) | ||
| CY1107082T1 (el) | Μεθοδος καθαρισμου αλβουμινης η οποια περιλαμβανει ενα σταδιο νανοδιηθησης, διαλυμα και συνθεση για θεραπευτικη χρηση που περιεχουν την ιδια | |
| JP2015500300A (ja) | アミロイドベータペプチド関連の疾患または症状の予防または治療のための医薬組成物 | |
| JP2005508872A5 (https=) | ||
| JP2007520539A5 (https=) | ||
| WO2009109493A3 (en) | 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists | |
| DE602004021358D1 (de) | Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen | |
| EP1670894A4 (en) | COMPOSITIONS COMPRISING VARIOUS TYPES OF TRANSFER FACTOR, METHODS FOR PREPARING COMPOSITIONS, AND METHODS OF TREATMENT USING THE COMPOSITIONS | |
| JP2018508556A5 (https=) |